Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.
Herpers
Bjorn L
BL
Department of Medical Microbiology and Immunology, St. Antonius Hospital, PO Box 2500, Nieuwegein 3430 EM, The Netherlands. b.herpers@antonius.net
Vlaminckx
Bart
B
Burkhardt
Olaf
O
Blom
Harmjo
H
Biemond-Moeniralam
Hazra S
HS
Hornef
Mathias
M
Welte
Tobias
T
Kuijper
Edward J
EJ
D000328:Adult; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D000529:Complementary Therapies / Q000379:methods; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078304:Tigecycline; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline